(Q28200610)

https://api.crossref.org/works/10.1111/J.1540-8183.2006.00181.X

Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1540-8183.2006.00181.X

Growth in clopidogrel-aspirin combination therapy

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1540-8183.2006.00181.X

Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1540-8183.2006.00181.X

Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1540-8183.2006.00181.X

Determinants of the interindividual variability in response to antiplatelet drugs

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1540-8183.2006.00181.X

Resistance to antiplatelet drugs: current status and future research

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1540-8183.2006.00181.X

Variability in response to aspirin: do we understand the clinical relevance?

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1540-8183.2006.00181.X

Low-dose aspirin for the prevention of atherothrombosis

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1540-8183.2006.00181.X

Aspirin resistance: position paper of the Working Group on Aspirin Resistance

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1540-8183.2006.00181.X

Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1540-8183.2006.00181.X

Platelet CD40 ligand (CD40L)--subcellular localization, regulation of expression, and inhibition by clopidogrel

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1540-8183.2006.00181.X

Clopidogrel inhibits platelet-leukocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndrome

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1540-8183.2006.00181.X

Limited early antiplatelet effect of 300 mg clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1540-8183.2006.00181.X

Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1540-8183.2006.00181.X

Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1540-8183.2006.00181.X

The difference between clopidogrel responsiveness and posttreatment platelet reactivity

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1540-8183.2006.00181.X

Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1540-8183.2006.00181.X

High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1540-8183.2006.00181.X

Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1540-8183.2006.00181.X

Enhanced shear-induced platelet aggregation in patients who experience subacute stent thrombosis: a case-control study

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1540-8183.2006.00181.X

Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1540-8183.2006.00181.X

Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1540-8183.2006.00181.X

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1540-8183.2006.00181.X

Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1540-8183.2006.00181.X

Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1540-8183.2006.00181.X

Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1540-8183.2006.00181.X

Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1540-8183.2006.00181.X

Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1540-8183.2006.00181.X

Effect of increasing doses of aspirin on platelet function as measured by PFA-100 in patients with diabetes

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1540-8183.2006.00181.X

Biological assessment of aspirin efficacy on healthy individuals: heterogeneous response or aspirin failure?

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1540-8183.2006.00181.X

Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1540-8183.2006.00181.X

Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1540-8183.2006.00181.X

A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1540-8183.2006.00181.X

The puzzle of aspirin and sex

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1540-8183.2006.00181.X

Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1540-8183.2006.00181.X

Profile and prevalence of aspirin resistance in patients with cardiovascular disease

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1540-8183.2006.00181.X

A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1540-8183.2006.00181.X

Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1540-8183.2006.00181.X

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1540-8183.2006.00181.X

Platelet activation in myocardial ischemic syndromes

21 April 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1540-8183.2006.00181.X

Signaling events underlying thrombus formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1540-8183.2006.00181.X

Platelet-active drugs : the relationships among dose, effectiveness, and side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1540-8183.2006.00181.X

Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1540-8183.2006.00181.X

Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1540-8183.2006.00181.X

The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1540-8183.2006.00181.X

Individual variations of platelet inhibition after loading doses of clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1540-8183.2006.00181.X

Frequency of nonresponse antiplatelet activity of clopidogrel during pretreatment for cardiac catheterization

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1540-8183.2006.00181.X

Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1540-8183.2006.00181.X

What is the best measure of thrombotic risks--pretreatment platelet aggregation, clopidogrel responsiveness, or posttreatment platelet aggregation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1540-8183.2006.00181.X

Hospital improvement in time to reperfusion in patients with acute myocardial infarction, 1999 to 2002

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1540-8183.2006.00181.X

Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1540-8183.2006.00181.X

High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1540-8183.2006.00181.X

Effects of low-to-high doses of aspirin on platelet aggregability and metabolites of thromboxane A2 and prostacyclin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1540-8183.2006.00181.X